Juergen Siebler
University of Mainz
11 Papers
158 Citations
Juergen Siebler is an academic researcher from University of Mainz. The author has contributed to research in topics: Hepatitis & T cell. The author has an hindex of 9, co-authored 10 publications.
Chat about Author
Papers
Treatment of nonalcoholic fatty liver disease
Juergen Siebler,Peter R. Galle +1 more
TL;DR: Weight reduction and physical activity to improve insulin sensitivity in obese patients should be the priority objective and a general recommendation for the application of specific drugs cannot be given.
Endoscopic full-thickness resection with an over-the-scope clip device (FTRD) in the colorectum: results from a university tertiary referral center.
TL;DR: FTRD is a minimally invasive approach with good success rate of complete resection and minimal side effects, as well as immediate or late complications in patients who underwent polyp removal with the FTRD.
Comparison of Hemospray® and Endoclot™ for the treatment of gastrointestinal bleeding.
Francesco Vitali,A. Naegel,Raja Atreya,Steffen Zopf,Clemens Neufert,Juergen Siebler,Markus F. Neurath,Timo Rath +7 more
TL;DR: Both HP allow for effective hemostasis with no differences in ST, LT success and re-bleeding.
42
IL-28A is a key regulator of T-cell-mediated liver injury via the T-box transcription factor T-bet.
Juergen Siebler,Stefan Wirtz,Benno Weigmann,Imke Atreya,Edgar Schmitt,Andreas Kreft,Peter R. Galle,Markus F. Neurath +7 more
TL;DR: IL-28A emerges as a key regulatory cytokine with pathogenic function in T-cell-mediated liver injury and represents a potential novel approach for therapy of Th1-mediated inflammatory diseases such as T- cell-mediated hepatitis.
40
Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer.
Markus Moehler,Ulrike Haas,Juergen Siebler,Christoph C. Schimanski,Christian Hertkorn,Thomas Hoehler,Peter R. Galle,Michael Heike +7 more
TL;DR: It is concluded that ILF is a feasible outpatient regimen with manageable toxicity that provides tumor control in a high proportion of patients with advanced gastric cancer, even among those with unfavorable prognostic features.
24